Protocol Ledger

NCT07095465 · Phase III · RECRUITING

Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

Interventional Phase III clinical trial protocol NCT07095465 sponsored by ACADIA Pharmaceuticals in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-11-14 Enrollment: 126 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07095465
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)126 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07095465
Protocol FieldVerified Registry Value
NCT IdentifierNCT07095465
Consolidated Lead SponsorACADIA Pharmaceuticals
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment126 participants (ESTIMATED)
Registered Start Date2025-11-14
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI